Additional Effects of Flutter With Conventional Chest Physiotherapy on Peak Expiratory Flow Rate and Chest Expansion in Post CABG Patients With COPD
NCT07875049
Summary
Flutter therapy is an oscillating positive expiratory pressure (OPEP) technique that combines positive expiratory pressure with airway oscillations to facilitate mobilization and clearance of respiratory secretions. Conventional chest physiotherapy includes deep breathing exercises, incentive spirometry, airway-clearance techniques, splinted coughing and early mobilization to promote lung expansion and secretion clearance. A total of 94 patients aged 40-70 years with mild-to-moderate COPD undergoing elective coronary artery bypass grafting (CABG) will be enrolled in this randomized controlled trial and will be randomly allocated into two groups, with 47 participants in each group. The intervention group will receive conventional chest physiotherapy combined with Flutter therapy, while the control group will receive conventional chest physiotherapy alone. Both groups will receive supervised treatment for 5 consecutive postoperative days, with 3 sessions per day, resulting in 15 treatment sessions. Baseline assessment will be performed on postoperative day 1 before commencement of the intervention, and post-intervention assessment will be conducted on postoperative day 5. The study will compare the effects of Flutter-assisted conventional chest physiotherapy versus conventional chest physiotherapy alone on postoperative peak expiratory flow rate, chest expansion and airway clearance.
Eligibility
Inclusion Criteria: * Adults aged 40-70 years undergoing elective CABG * Pre-existing COPD (mild- moderate), clinically diagnosed COPD * Early post-operative (24-72 hrs.), extubated and hemodynamically stable * No mechanical ventilation beyond 24 hrs., stable vitals (HR: 60-100bpm, SBP :110-130mmhg), no vasopressors. * Follow commands, provide consent and perform assessments. Exclusion Criteria: * Patients undergoing emergency CABG or revision/repeat CABG procedure * Patients with severe COPD or intersitial lung disease * Contraindications positive expiratoey pressure (PEP) therapy (e.g, untreated pneumothorax, hemoptysis or recent esophageal surgery). * Hemodynamically unstable patients post-operatively. * Patients with neurological, musculoskeletal or cognitive impairments. * Patients with active infections, malignancy. * Patients with severe or uncontrolled comorbidities(e.g; renal failure). * Patients in BiPAP.
Conditions5
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07875049